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Chorioamnionitis is a major risk factor for preterm birth and an independent risk factor
for postnatal morbidity for which currently successful therapies are lacking. Emerging
evidence indicates that the timing and duration of intra-amniotic infections are crucial
determinants for the stage of developmental injury at birth. Insight into the dynamical
changes of organ injury after the onset of chorioamnionitis revealed novel therapeutic
windows of opportunity. Importantly, successful development and implementation of
therapies in clinical care is currently impeded by a lack of diagnostic tools for early
(prenatal) detection and surveillance of intra-amniotic infections. In the current study
we questioned whether an intra-amniotic infection could be accurately diagnosed by
a specific volatile organic compound (VOC) profile in exhaled breath of pregnant sheep.
For this purpose pregnant Texel ewes were inoculated intra-amniotically withUreaplasma
parvum and serial collections of exhaled breath were performed for 6 days. Ureaplasma
parvum infection induced a distinct VOC-signature in expired breath of pregnant sheep
that was significantly different between day 0 and 1 vs. day 5 and 6. Based on a profile
of only 15 discriminatory volatiles, animals could correctly be classified as either infected
(day 5 and 6) or not (day 0 and 1) with a sensitivity of 83% and a specificity of 71% and
an area under the curve of 0.93. Chemical identification of these distinct VOCs revealed
the presence of a lipid peroxidation marker nonanal and various hydrocarbons including
n-undecane and n-dodecane. These data indicate that intra-amniotic infections can be
detected by VOC analyses of exhaled breath and might provide insight into temporal
dynamics of intra-amniotic infection and its underlying pathways. In particular, several
of these volatiles are associated with enhanced oxidative stress and undecane and
dodecane have been reported as predictive biomarker of spontaneous preterm birth
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in humans. Applying VOC analysis for the early detection of intra-amniotic infections
will lead to appropriate surveillance of these high-risk pregnancies, thereby facilitating
appropriate clinical course of action including early treatment of preventative measures
for pre-maturity-associated morbidities.
Keywords: preterm birth, non-invasive diagnostics, exhaled breath volatile organic compound, chorioamnionitis,
biomarker
INTRODUCTION
Chorioamnionitis, inflammation associated with an intra-uterine
infection of the amniotic fluid and fetal membranes is a major
risk factor for preterm birth and an independent risk factor
for postnatal disorders such as chronic lung disease, necrotizing
enterocolitis, and periventricular leukomalacia (1–3). Incidences
of chorioamnionitis are inversely related to gestational age (GA)
at birth ranging from an incidence of >70% at 24 weeks GA to
16% at 34 weeks GA (4).
Only a small proportion of pregnant women with preterm
birth show clinical signs of chorioamnionitis such as maternal
fever, uterine fundal tenderness, maternal tachycardia, fetal
tachycardia, and purulent or foul amniotic fluid (5). However,
preterm birth is most frequently the result of a clinically
unapparent histological chorioamnionitis (6, 7). In these cases,
evidence for the presence of chorioamnionitis becomes available
only after delivery. More precisely, post-partum histological
examination of the placenta with evidence of inflammation and
necrosis throughout the chorionic plate and amnion is currently
the gold standard to diagnose chorioamnionitis (5).
There is emerging evidence that the timing and duration
of intra-amniotic infections are crucial determinants for
developmental injury at birth (8, 9). Moreover, we and
others have successfully tested in utero therapies to prevent
or treat chorioamnionitis-induced lung and gut injury (10–
12). These combined findings highlight that identification
of chorioamnionitis at the earliest time point, being in
utero is essential for optimal treatment and prevention of
organ injury during pregnancy or after birth. Collectively,
early identification of chorioamnionitis during pregnancy will
extend the time window for clinicians to decide and institute
the appropriate clinical course of action to (1) prevent of
delay preterm birth and (2) improve outcomes for preterm
born neonates.
In recent years, there is increasing attention for non-
invasive biomarkers. Exhaled breath consists of volatile
organic compounds (VOCs), which are formed during various
inflammatory and metabolic processes on a cellular and systemic
level (13). In adults and older children, the study of metabolomics
using exhaled VOCs is known to be such a safe and non-invasive
procedure to evaluate ongoing processes of inflammation
and oxidative stress (14), which are key requirements for the
induction of cystic fibrosis, asthma and chronic obstructive
pulmonary disease (15–17). In addition, profiling exhaled
VOCs has been applied successfully in the diagnosis of chronic
diseases of the intestine (18, 19), liver (20), kidney (21), pancreas
(diabetes) (22, 23) and neurodegenerative diseases (24–26).
Using a well-established pre-clinical model of
chorioamnionitis, we questioned whether an intra-amniotic
infection could be accurately diagnosed by a specific VOC profile
in exhaled breath of pregnant sheep.
METHODS AND MATERIALS
Animals
The animal study, including sampling of exhaled breath, and
experimental protocols were in line with the guidelines for
animal experiments and approved by the Central Authority for
Scientific Procedures on Animals and the animal welfare body
of Maastricht University. For this proof-of-concept study, we
did not perform a power calculation. Within the context of
good laboratory animal practice and the 3R principle we did not
plan a separate animal study but rather made use of sheep that
destined for another study published by Hütten et al. (27). Power
calculations were performed for this initial study and a power of
n= 6 per experimental group was considered adequate.
Six date-mated Texel ewes (n = 5 singleton; n = 1 twin
pregnancy) underwent ultrasound-guided intra-amniotic
injection with 5.0∗105 color-changing units (CCU) of
Ureaplasma parvum (UP) (strain HPA5) as reported previously
(12, 27). In case of twin pregnancy, both uterine horns were
inoculated with UP. Amniotic fluid was collected prior to UP
injection and during Cesarean section and cultured for UP
quantification (28). All animals were group-housed in the same
stable under standardized conditions with a 12-h dark/light cycle
and had ad libitum access to food and water. During sampling
procedure, the animals were restrained by experienced care
takers to avoid stress. Six days after intra-amniotic injection (129
days GA) fetuses were delivered preterm by Cesarean section
under general anesthesia and used for experimental protocols
detailed previously (27). At birth, no sex (3 males and 4 females)
and bodyweight (3,270 ± 611 g) differences were observed
between all lambs.
Exhaled Breath Sampling
Exhaled breath was collected prior to injection, for baseline
(control) measurements, and then daily for 6 days (Figure 1A)
after injection. As such, each sheep serves as its own internal
reference. During breath collection, animals were monitored for
physical signs of eructation. In case of eructation, the sample
was discarded as this might negatively influence the VOC profile
(29). Breath was collected via a customized veterinary mouth-
nose mask (Koo Medical Equipment, Arese, Italy) connected
to a non-rebreathing valve (Ruben Valve, Intersurgical Ltd.,
Wokingham, Berkshire UK) and an inert 5L Tedlar (Tedlar
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FIGURE 1 | Experimental design. (A) Time-mated Texel ewes were given an intra-amniotic injection of UP (5.0*105 CCU). Prior to (t = 0) and daily for 6 days after
injection, exhaled breath was collected by inflation of 5L Tedlar back through a mouth-nose mask connected to a two-way non-rebreathing valve. Six days (t = 6) after
intra-amniotic UP-exposure, fetus were delivered by Cesarean section and used for experimented reported elsewhere (27). Group 1 (n = 4) was sampled first,
followed by group 2 at a later time point. (B) Illustrative picture of exhaled breath collection in UP-exposed sheep. VOC, volatile organic compound; UP, U. Parvum.
Bag, SKC Ltd., Dorset, UK) gas-sampling bag (Figure 1B).
Immediately after breath sampling, the contents of the bag
were transferred onto a stainless steel two-bed desorption tube
filled with carbograph 1TD/Carbopack X (Markes International,
Llantrisant Business Park, UK) using a pump at a constant flow of
= 200ml/min. The tubes were then air-tight capped and stored at
room temperature until further analysis. Between exhaled breath
collections, the sampling bags and masks were flushed three
times with high-grade nitrogen to ensure that all contaminants
were eliminated.
The samples collected at each time point from different
animals were collected at the same location in a random order
to minimize confounding variable error mediating bias. Timing
of exhaled breath collections was between 09.00 and 11.00 to
minimize diurnal variations between samplings.
The current study involved two groups of animals, a discovery
set to define the parameters and a separate confirmation set to
test the rigor of the selected discriminators. All animals followed
the same protocol for modeling experimental chorioamnionitis
and exhaled breath sampling.
Analysis of Exhaled Breath Samples
The volatile metabolites in exhaled breath were
measured using gas chromatography time-of-flight mass
spectrometry (GC-tof -MS). All samples were measured in
random order.
Before the measurements by GC-tof -MS, all sorbent tubes
were purged for 5min to remove water. To remove the volatile
metabolites trapped on the sorption tubes automated thermal
desorption TD 100 for industry standard (Markes International,
Llantrisant, Wales, UK) under a flow of helium was used. The
tubes were heated at 270◦C to release the VOCs. The vapor
containing the released VOCs was then divided into two parts.
The first part, consisting of 25% of the released VOCs, was
collected in a cold trap at 5◦C, whereas the other 75% was re-
collected into the identical stainless steel two-bed desorption
tube. Of the part of VOCs sample collected in the cold trap, 75%
was injected in the Gas Chromatogram column at a temperature
of 300◦C and separated by capillary gas chromatography
(column: RTX-5ms, 30m × 0.25mm 5% diphenyl, 95%
dimethylsiloxane, film thickness 1m; Trace 1300GC, Thermo
Fisher Scientific, Waltham, Massachusetts). The temperature
gradient for the gas chromatograph was programmed in the
following manner: 40◦C for 5min, then raised with 10◦C/min
to a maximum temperature of 270◦C, which was maintained for
5min. Time-of-flight mass spectrometry (tof -MS; Bench TOF-
dx, Almsco International, Llantrisant, Wales, UK) was used to
detect and identify compounds available in the samples. Electron
ionization mode was set at 70 eV and the mass range 35–350
m/z was measured. Sample frequency of the mass spectrometer
was set to 5 scans/s and analysis run time to 33min. Following
this procedure, a chromatogram was generated for each breath
sample of each animal.
Data Pre-processing and Statistical
Analysis
The raw chromatograms obtained by GC-tof -MS were first pre-
processed to diminish the effect of various artifacts including
noise and baseline, column bleeding, and chromatographic
shifts. The detailed description of data pre-processing steps
can be found elsewhere (30). The GC-tof -MS data after noise
removal and baseline correction were further transformed by
calculating the area under the peak. These calculated areas for
each peak were matched from sample to sample based on the
similarity in retention time and Pearson correlation between the
mass spectra. A high correlation (>85%) was used to consider
peaks as the same compounds. The last step was the creation
of a data matrix with samples/animals in rows and relative
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FIGURE 2 | Intra-amniotic UP-exposure leads to gut inflammation. (A) In control fetuses, MPO-positive cells were predominantly located in the lower crypt region. (B)
Six days after intra-amniotic UP-exposure, increased numbers MPO positive cells were observed in the lower crypt. In addition, influx of MPO positive cells into the villi
was observed following UP-exposure, which was absent in non-infected historical controls. Images were taken at 100 times magnification, scale bar represents
200µm. Insert images were taken at 400 times magnification. MPO, myeloperoxidase; UP, U. Parvum.
concentrations of measured volatiles metabolite (ion counts)
in columns.
Data obtained for group 1 and group 2 consisted of baseline
measurements, pre-injection samples, and six consecutive post-
injection sampling days (labeled T1, T2, T3, T4, T5, and T6,
Figure 1). The animals from group 1 was used as the discovery
set, i.e., finding specific VOCs related to chorioamnionitis,
while animals in group 2 served as an independent test
set i.e., evaluating the predictive power of the selected
exhaled VOCs.
The statistical analysis consisted of performing random forest
(RF) analysis (31) with 500 trees using exhaled breath samples
of group 1. The classification model comprised of finding
the exhaled breath VOCs capable to discriminate pre-infection
samples (baseline) and post-infection samples corresponding
to development of chorioamnionitis. The classification model
was first internally validated using so called out-of-bag (oob)
samples. For each RF tree one-third of the training samples were
left out and not used in the construction of the classification
model. The most discriminatory exhaled VOCs were selected
looking at the importance index obtained in RF model (32). The
final RF model containing the set of the most discriminatory
VOCs was validated using independent test set consisting of
samples of group 2. The final performance of the model
was expressed in sensitivity, specificity and receiver operating
characteristic curve (ROC). To visualize the differences between
pre-infection and post-infection samples Principal Component
Analysis (PCA) score plot was used. PCA is a workhorse
technique within various -omics related fields. This technique
reduces data dimensionality by means of Principal Components
(PCs), while preserving as much variability as possible. The
PCs are the linear combination of the original parameters
(here VOCs measured in exhaled breath). The PCA score plot




In accordance with several earlier studies (12, 33–35), intra-
amniotic infection following intra-amniotic UP administration
was confirmed by the presence of UP in amniotic fluid
during Cesarean section. No endogenous UP was detected
in the amniotic fluid prior to inoculation (data not shown).
Experimental induction of chorioamnionitis following
intrauterine inoculation of UP is a well-established model
and has been shown to induce systemic organ inflammation,
including in the intestine (12, 36). Consistent with these earlier
reports, gut inflammation at 6 days post UP infection was
detected, confirming the phenotype of the model (Figure 2).
Exhaled Breath
In this study 544 different VOCs were detected in exhaled breath
of 4 animals. To increase the group size, the possibility of
combining the baseline and T1 samples to define pre-infection
class and T5 and T6 time points into post-infection class was
investigated. The differences in breath profile between baseline
and T1 samples as well as between T5 and T6 samples were
investigated by regularized multivariate analysis of variance
(rMANOVA). The rMANOVA indicated no statistical differences
between baseline and T1 samples (p-value of 0.15) as well as
between T5 and T6 samples (p-value of 0.12).
In Figure 3 the averaged VOC profiles for pre-infection
(baseline samples) and post-infection (T6) samples are shown.
As could be expected the VOC profiles of baseline samples,
i.e., exhaled breath taken before intra-amniotic UP injection
and samples taken at T6, i.e., 6 days after intra-amniotic UP
injection were similar. Note, that here the overall averaged profile
is visually assessed. The largest differences can be seen in the
chromatograms at retention time two and 20 min.
The classification model let to the selection of 15 exhaled
VOCs. The final RF model was built using the most
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FIGURE 3 | The averaged VOCs profiles for pre-infection (black) and
post-infection samples (red). The largest differences in averaged profiles is
seen at retention time (RT, i.e., time after compounds captured in exhaled
breath pass through a chromatographic column) 2min and 20 indicated by
circles.
discriminatory set of 15 VOCs. In order to visualize the
differences between pre-infection (baseline and T1) and post-
infection (T5 and T6) samples, PCA analysis was performed
using the set of 15 discriminatory VOCs. The corresponding
PCA score plot is shown in Figure 4A. As can be seen the
pre-infection and post-infection samples are separated among
PC1, which explains almost 35% of the data variance (i.e.,
information contained in the data). Since PC1 always explains
the majority of the variance in the data, this result indicates
that it corresponds to the differences in the development of
infection. The validity of the selected set of 15 discriminatory
compounds was tested using the independent test set, consisting
of new group of animals sampled following the same protocol
as the discovery group (group 2). The external validation of
the findings resulted in the ROC curve with an area of 0.93
and sensitivity and specificity of 83.3 and 71.4%, respectively
(Figure 4B). The previous time points, T2 and T3, did not show
a clear distinction of UP infection using the set of 15 VOCs. The
following time point, T4, showed good accuracy of predicting
UP infection with accuracy of 0.7. The PCA score plot obtained
for pre-infection and post-infection data with projected samples
from T4 is shown in Figure 5.
The putative chemical identification of the set of the 15 most
discriminatory VOCs was performed using spectrum recognition
using the National Institute of Standards and Technology library
in combination with spectrum interpretation by an experienced
mass-spectrometrist and identification based on retention times
of compounds. From a set of 15 VOCs it was possible to
chemically identify 11 of them while four remain unknown.
These 4 compounds could not be identified due to insufficient
mass spectrum, overlap in the retention time or absence of mass
spectrum in the library. Moreover, six compounds could be only
identified as their global formula and the exact chemical structure
remains uncharacterized. Table 1 shows the list of 15 identified
VOCs and their relative concentrations change in breath samples
obtained from pre-infection and post-infection samples. Up or
down regulation of relative VOC concentration is indicated as
(+) or (–), respectively, with reference to the infected animal. As
can be observed the discriminatory compounds belong mostly to
different alkanes and aldehydes.
To further investigate whether the relative amounts of
the individual VOCs are significantly different between pre-
infection and post-infection samples, a rank test was used.
The corresponding p-values are indicated in Table 1. As can
be observed the discriminatory compounds belong mostly
to different alkanes, alcohol and aldehydes, with the relative
concentration of the majority of the compounds being elevated
in exhaled breath of the post-infection samples.
Discussion/Conclusion
Chorioamnionitis is an important risk factor for preterm birth
and prematurity-associated disorders such as bronchopulmonary
dysplasia, necrotizing enterocolitis, and neurological injury
(1, 3, 37). Currently, chorioamnionitis is diagnosed by postnatal
histological assessment of the placenta and membranes.
Consequently, data on the presence of chorioamnionitis
become available postnatally, and do not provide information
on timing of onset and duration of infection. This latter
aspect is of key importance since information on timing and
duration of infection are critical determinants for initiation of
optimal treatment regimes in preterm infants. Moreover, timely
diagnosis and treatment of intra-amniotic infections as the
main underlying mechanisms of preterm birth using antibiotic
treatment and fetal delivery has shown to improve maternal and
neonatal outcomes (38).
Several pre-clinical studies showed that interventions at
the earliest possible moment, being in utero, have been
successfully tested (10–12, 39–44). Successful development
and implementation of such treatment strategies in clinical
care is currently impeded by a lack of diagnostic tools for
early (antenatal) detection and surveillance of intra-amniotic
infections. As such, we aimed to develop a diagnostic tool for
early (antenatal) recognition of this distinct risk factor in utero
in a safe and non-invasive manner.
In the current proof-of-concept study, we demonstrated that
intra-amniotic UP infection induces a distinct VOC-signature
in exhaled breath of pregnant sheep. Based on the identified
profile of 15 discriminatory volatiles, animals could correctly
be classified as either infected or not with good sensitivity
(83.3%) and specificity (71.4%). Importantly, we were capable
of differentiating UP infection with very good accuracy of 0.7
from 4 post-infection onwards. The prediction performance of
UP infection by the VOCs profile was indeterminate 72 h post-
infection (data not shown). Those findings indicate that the UP
infection can be detectable with good accuracy using exhaled
breath profile from 96 h onwards post-infection. The discovery
of a distinct VOC profile to determine and monitor an intra-
amniotic UP infection extends recent clinical studies by Lacey
et al. in which they demonstrated that VOC testing of vaginal
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FIGURE 4 | (A) Principal component analysis (PCA) score plot score plot obtained from breathogram belonging to pre-infection (i.e., baseline; asterisk) and
post-infection (T5-6; black dot) using a set of 15 discriminatory VOCs; (B) Receiver operating characteristic curve (ROC) of the independent test samples of the final
random forest (RF) model obtained pre-infection and post-infection samples using the set of 15 discriminatory VOCs. The area under the curve is 0.93.
swabs can be used to predict group B streptococcus infection
during pregnancy (45) and detect bacterial vaginosis which was
linked to preterm labor (46).
Among the identified VOCs associated with UP-infection
are various alkenes, aldehyde and alcohols which are primary
and secondary products of the lipid peroxidation. The elevated
level of the lipid peroxidation marker nonanal and various
hydrocarbons including the identified n-undecane and n-
dodecane is in line with the concept that intra-uterine infection
induces higher level of oxidative stress. The presence of
these volatiles indicates the occurrence of oxidative stress,
a process defined as an imbalance between the production
of and the protection against reactive oxygen species in
favor of the first (47) and associated with inflammation (48).
Chorioamnionitis-induced oxidative stress has been shown to
play an important role in preterm labor (49) and its occurrence
has recently been underlined in a human study associating
placental lesions due to chorioamnionitis with higher levels
of oxidative stress biomarkers in cord blood of neonates (50).
More closely to our setup, the induction of systemic oxidative
stress and modest lung oxidative stress, potentially contributing
to bronchopulmonary dysplasia (BPD), by intra-amniotic
endotoxin has been demonstrated in fetal lambs (51, 52). This
alleged involvement of oxidative stress in chorioamnionitis-
induced preterm labor and potential development of BPD
implies prospective antioxidant supplementation might be a
good strategy in the future to protect preterm newborns from
severe lung damage (48). This approach highlights the role of
antenatal identification of women at risk of chorioamnionitis
using the non-invasive markers, such as VOC profiles
in breath.
Interestingly, due to the direct link between inflammation and
oxidative stress, the volatile undecane has been associated with
FIGURE 5 | PCA score plot obtained from breathogram belonging to
pre-infection (day 0 and 1; black square) and post-infection (day 5 and 6;
asterisk) samples and projected samples of animals at day 4 (T4; cross) using
a set of 15 discriminatory VOCs. As can be seen majority of the samples are
projected in the space belonging to the post-infection samples.
both processes in general. This is especially the case for infections
caused by viruses though, as they do not produce their own
metabolites but instead hijack themetabolism of the host, thereby
enhancing processes such as glycolysis and oxidative stress (53).
Although various studies have already been performed to identify
volatile markers unique for specific bacterial strains, n-undecane
has not yet been reported as possible biomarker specific for any
of the pathogens tested until now (54–56). However, UP has not
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TABLE 1 | A list of 15 discriminatory VOCs, their putative identification, statistical
significance (indicated as p-value obtained from rank test after correction for
multitesting with Benjamin-Hochberg) and their relative concentration change in
post-infection group with respect to pre-infection samples.
Nr. Compound name Compound change in
infected group
p-value
1 1-butanol (–) 0.22
2 Nonanal* (+) 0.02
3 n-undecan* (+) 0.02
4 n-dodecan (+) 0.06
5 6-tridecene (+) 0.09
6 C10H18O (+) 0.07
7 C10H14 (+) 0.07
8 C11H24 (branched)* (–) 0.02
9 C15H24 (+) 0.98
10 C9H18 (branched) (+) 0.07
11 C5H7COOH (+) 0.15
12 Unknown (–) 0.98
13 Unknown* (+) 0.04
14 Unknown* (+) 0.02
15 Unknown* (–) 0.03
*Corresponds to compounds statistically significant.
been included in such investigations thus far, indicating it might
be useful to investigate whether undecane is indeed specifically
produced by this pathogen or a byproduct of the oxidative stress
induced by this bacterium instead.
Finally, the volatiles undecane and dodecane that were
discriminative between pre-infection and post-infection samples
in our study have recently been reported as predictive biomarker
of spontaneous preterm birth in humans (57). In that study,
the maternal serum metabolome was studied at 15- and 20-
weeks’ gestation in an attempt to identify biomarkers for an
increased risk of spontaneous preterm birth, which may lead to
enhanced neonatal morbidities including BPD, in asymptomatic
nulliparous women in 2 different cohorts. In one of the cohorts,
the alkanes undecane, dodecane, and decane were associated with
spontaneous preterm birth whereas these elevated levels could
not be observed in the other cohort. Consequently, the study
did not provide enough evidence yet to use these alkanes as
clinical predictor but does underline once more the relationship
between oxidative stress and the risk of neonatal morbidity and
mortality (57).
Strengths of the current study are (1) the controlled
environment of the established model that is free of confounding
factors including behavioral and dietary influences; (2)
establishment of individual baseline measurements prior to
intra-amniotic infection; (3) the use of a precisely regulated
amount of UP, which are the most common microorganisms
isolated in cases of spontaneous (asymptomatic) preterm
birth (58–60) and significantly associated with histological
chorioamnionitis (60); (4) the use of a sampling technique
that is used in clinical practice; and (5) the use of a simple,
non-invasive, and repeatedly obtained sample medium, being
exhaled air, which will appeal to patients. A limitation is that
a number of VOCs remained incompletely characterized.
Still, the identified VOCs could serve as specific markers for
chorioamnionitis, and UP infections specifically, and could thus
be applied for future human exhaled breath studies. Future
pre-clinical studies should extend on the current findings
and look for further discriminative markers by (1) increasing
the experimental power; (2) taking the polymicrobial nature
of intra-amniotic infections into account; and (3) focus on
discerning timing of onset of infection or duration of infection,
which are essential elements that determine organ outcomes
at birth. Moreover, combining exhaled VOCs with peri-
partum diagnostic tools, including amniotic fluid parameters,
might aid in the diagnosis of (subclinical) chorioamnionitis.
Furthermore, extending the time window of VOC profiling
post-partum might provide essential insight into maternal
recovery from chorioamnionitis and contribute to risk profiling
for women at risk of developing post-partum endometritis,
which is the most common post-partum complication following
chorioamnionitis, thereby allowing selective use of prophylactic
antibiotics (61, 62).
CONCLUSION
With 15 million cases globally, preterm birth remains a
major health care problem (63) with chorioamnionitis as its
most important risk factor. Analyses of VOCs in exhaled
breath of pregnant sheep shows great potential to identify
pregnancies complicated by intra-amniotic infections and
clinical implementation would be an immense breakthrough in
perinatal diagnostics. Early detection of intra-amniotic infections
with point-of-care VOC testing, potentially combined with
peri-partum amniotic fluid biomarkers indicative for intra-
amniotic infection (64), will lead to optimal surveillance of
these high-risk pregnancies and will facilitate appropriate
clinical management including antibiotic treatment and timely
treatment or preventative measures for pre-maturity-associated
morbidities. A clinical study in a high risk pregnancy population,
defined by (1) chorioamnionitis in previous pregnancies; (2)
asymptomatic cervical shortening; and (3) prolonged rupture
of membranes has been planned to verify the results from this
proof-of-concept study in combination with intra- and post-
partum diagnostic techniques that are currently in practice,
including clinical parameters, amniotic fluid parameters, and
placenta histology (5, 64).
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
ETHICS STATEMENT
The animal study was reviewed and approved by Central
Authority for Scientific Procedures on Animals and the animal
welfare body of Maastricht University.
Frontiers in Pediatrics | www.frontiersin.org 7 May 2021 | Volume 9 | Article 617906
Ophelders et al. Exhaled VOC to Detect Chorioamnionitis
AUTHOR CONTRIBUTIONS
DO, AB, and TW conceived original idea. DO and MH
performed ultrasound-guided injections with UP, which was
provided by OS. DO collected and processed exhaled breath
for laboratory analyses. AB, AS, and F-JS supervised laboratory
analyses on exhaled breath. DO, AB, MH, SA-N, RJ, OS, F-JS, AS,
and TW contributed to the interpretation of the results. DO and
AB wrote the manuscript with input from all authors. DO and
TW supervised the project. All authors read, and approved the
submitted version.
FUNDING
This work was supported by the CZ health insurance fund
(Project Number 201500240) (TW).
ACKNOWLEDGMENTS
We would like to thank Monique Lecluijze for her excellent
assistance with the ultrasound-guided intra-amniotic injections
and Prof. Dr. Boris W. Kramer for acquisition of the sheep which
were originally used for a study by Hütten et al. (27).
REFERENCES
1. Jobe AH, Bancalari EJ. Bronchopulmonary dysplasia. Am J Respir Crit Care
Med. (2001) 163:1723–9. doi: 10.1164/ajrccm.163.7.2011060
2. Volpe JJ. The encephalopathy of prematurity–brain injury and impaired
brain development inextricably intertwined. Semin Pediatr Neurol. (2009)
16:167–78. doi: 10.1016/j.spen.2009.09.005
3. Been JV, Lievense S, Zimmermann LJ, Kramer BW, Wolfs TG.
Chorioamnionitis as a risk factor for necrotizing enterocolitis: a
systematic review and meta-analysis. J Pediatr. (2013) 162:236–
42.e232. doi: 10.1016/j.jpeds.2012.07.012
4. Lahra MM, Jeffery HEJ. A fetal response to chorioamnionitis is associated
with early survival after preterm birth. Am J Obstet Gynecol. (2004) 190:147–
51. doi: 10.1016/j.ajog.2003.07.012
5. Tita AT, Andrews WW. Diagnosis and management of
clinical chorioamnionitis. Clin Perinatol. (2010) 37:339–
54. doi: 10.1016/j.clp.2010.02.003
6. Hagberg H,Wennerholm U-B, Sävman K. Sequelae of chorioamnionitis. Curr
Opin Infect Dis. (2002) 15:301–6. doi: 10.1097/00001432-200206000-00014
7. Romero R, Gotsch F, Pineles B, Kusanovic JP. Inflammation in pregnancy: its
roles in reproductive physiology, obstetrical complications, fetal injury. Nutr
Rev. (2007) 65:S194–202. doi: 10.1111/j.1753-4887.2007.tb00362.x
8. Gussenhoven R, Westerlaken RJ, Ophelders DR, Jobe AH, Kemp MW,
Kallapur SG, et al. Chorioamnionitis, neuroinflammation, and injury:
timing is key in the preterm ovine fetus. J Neuroinflammation. (2018)
15:113. doi: 10.1186/s12974-018-1149-x
9. Heymans C, De Lange I, Lenaerts K, Kessels L, Hadfoune M, Rademakers
G, et al. Chorioamnionitis induces enteric nervous system injury: effects
of timing and inflammation in the ovine fetus. Mol Med. (2020) 26:1–
10. doi: 10.1186/s10020-020-00206-x
10. Nikiforou M, Vanderlocht J, Chougnet CA, Jellema RK, Ophelders DR,
Joosten M, et al. Prophylactic interleukin-2 treatment prevents fetal gut
inflammation and injury in an ovine model of chorioamnionitis. Inflamm
Bowel Dis. (2015) 21:2026–38. doi: 10.1097/MIB.0000000000000455
11. Willems MG, Ophelders DR, Nikiforou M, Jellema RK, Butz A, Delhaas
T, et al. Systemic interleukin-2 administration improves lung function
and modulates chorioamnionitis-induced pulmonary inflammation in the
ovine fetus. Am J Physiol Lung Cell Mol Physiol. (2015) 310:L1–
7. doi: 10.1152/ajplung.00289.2015
12. Van Gorp C, De Lange IH, Spiller OB, Dewez F, Cillero Pastor B,
Heeren R, et al. Protection of the ovine fetal gut against ureaplasma-
induced chorioamnionitis: a potential role for plant sterols. Nutrients. (2019)
11:968. doi: 10.3390/nu11050968
13. Boots AW, Bos LD, Van Der Schee MP, Van Schooten F-
J, Sterk PJ. Exhaled molecular fingerprinting in diagnosis and
monitoring: validating volatile promises. Trends Mol Med. (2015)
21:633–44. doi: 10.1016/j.molmed.2015.08.001
14. Mazzatenta A, Pokorski M, Di Giulio, C. Real time analysis of volatile
organic compounds (VOCs) in centenarians. Respir Physiol Neurobiol. (2015)
209:47–51. doi: 10.1016/j.resp.2014.12.014
15. Mazzatenta A, Di Giulio C, Pokorski M. Pathologies
currently identified by exhaled biomarkers. Respir Physiol
Neurobiol. (2013) 187:128–34. doi: 10.1016/j.resp.2013.
02.016
16. Van De Kant KD, Van Berkel JJ, Jöbsis Q, Passos VL, Klaassen EM, Van
Der Sande L, et al. Exhaled breath profiling in diagnosing wheezy preschool
children. Eur Respir J. (2013) 41:183–8. doi: 10.1183/09031936.00122411
17. Smolinska A, Klaassen EM, Dallinga JW, Van De Kant KD, Jobsis Q, Moonen
EJ, et al. Profiling of volatile organic compounds in exhaled breath as a strategy
to find early predictive signatures of asthma in children. PLoS ONE. (2014)
9:e95668. doi: 10.1371/journal.pone.0095668
18. Bodelier AG, Smolinska A, Baranska A, Dallinga JW, Mujagic Z, Vanhees K,
et al. Volatile organic compounds in exhaled air as novel marker for disease
activity in Crohn’s disease: a metabolomic approach. Inflamm Bowel Dis.
(2015) 21:1776–85. doi: 10.1097/MIB.0000000000000436
19. Arasaradnam RP, Mcfarlane M, Daulton E, Skinner J, O’connell N, Wurie
S, et al. Non-invasive exhaled volatile organic biomarker analysis to
detect inflammatory bowel disease (IBD). Dig Liver Dis. (2016) 48:148–
53. doi: 10.1016/j.dld.2015.10.013
20. Pijls KE, Smolinska A, Jonkers DM, Dallinga JW, Masclee AA, Koek
GH, et al. A profile of volatile organic compounds in exhaled air as
a potential non-invasive biomarker for liver cirrhosis. Sci Rep. (2016)
6:19903. doi: 10.1038/srep19903
21. Obermeier J, Trefz P, Happ J, Schubert JK, Staude H, Fischer D-
C, et al. Exhaled volatile substances mirror clinical conditions
in pediatric chronic kidney disease. PLoS ONE. (2017)
12:e0178745. doi: 10.1371/journal.pone.0178745
22. Minh TDC, Blake DR, Galassetti PR. The clinical potential of exhaled
breath analysis for diabetes mellitus. Diabetes Res Clin Pract. (2012) 97:195–
205. doi: 10.1016/j.diabres.2012.02.006
23. Mazzatenta A, Pokorski M, Di Giulio C. Real-time breath analysis in type 2
diabetes patients during cognitive effort. Adv Exp Med Biol. (2013) 788:247–
53.
24. Mazzatenta A, Pokorski M, Sartucci F, Domenici L, Di Giulio, C.
Volatile organic compounds (VOCs) fingerprint of Alzheimer’s disease.
Respir Physiol Neurobiol. (2015) 209:81–4. doi: 10.1016/j.resp.2014.
10.001
25. Invitto S, Mazzatenta A. Olfactory event-related potentials and exhaled
organic volatile compounds: the slow link between olfactory perception and
breath metabolic response. A pilot study on phenylethyl alcohol and vaseline
oil. Brain Sci. (2019) 9:84. doi: 10.3390/brainsci9040084
26. Tiele A, Wicaksono A, Daulton E, Ifeachor E, Eyre V, Clarke S, et al. Breath-
based non-invasive diagnosis of Alzheimer’s disease: a pilot study. J Breath Res.
(2020) 14:026003. doi: 10.1088/1752-7163/ab6016
27. Hütten MC, Fehrholz M, Konrad FM, Ophelders D, Kleintjes C, Ottensmeier
B, et al. Detrimental effects of an inhaled phosphodiesterase-4 inhibitor on
lung inflammation in ventilated preterm lambs exposed to chorioamnionitis
are dose dependent. J Aerosol Med Pulmonary Drug Delivery. (2019) 32:395–
404. doi: 10.1089/jamp.2019.1528
28. Miura Y, Payne MS, Keelan JA, Noe A, Carter S, Watts R, et al.
Maternal intravenous treatment with either azithromycin or solithromycin
clears Ureaplasma parvum from the amniotic fluid in an ovine model
of intrauterine infection. Antimicrob Agents Chemother. (2014) 58:5413–
20. doi: 10.1128/AAC.03187-14
Frontiers in Pediatrics | www.frontiersin.org 8 May 2021 | Volume 9 | Article 617906
Ophelders et al. Exhaled VOC to Detect Chorioamnionitis
29. Oertel P, Küntzel A, Reinhold P, Köhler H, Schubert JK, Kolb J,
et al. Continuous real-time breath analysis in ruminants: effect
of eructation on exhaled VOC profiles. J Breath Res. (2018)
12:036014. doi: 10.1088/1752-7163/aabdaf
30. Smolinska A, Hauschild AC, Fijten RR, Dallinga JW, Baumbach J,
Van Schooten, FJ. Current breathomics–a review on data pre-processing
techniques and machine learning in metabolomics breath analysis. J Breath
Res. (2014) 8:027105. doi: 10.1088/1752-7155/8/2/027105
31. Breiman L. Random forests. Machine Learning. (2001) 45:5–
32. doi: 10.1023/A:1010933404324
32. Stavropoulos G, Van Vorstenbosch R, Van Schooten F, Smolinska A. Random
Forest and Ensemble Methods. Amsterdam: Elsevier (2020).
33. Robinson JW, Dando SJ, Nitsos I, Newnham J, Polglase GR, Kallapur
SG, et al. Ureaplasma parvum serovar 3 multiple banded antigen size
variation after chronic intra-amniotic infection/colonization. PLoS ONE.
(2013) 8:e62746. doi: 10.1371/journal.pone.0062746
34. Gussenhoven R, Ophelders DRMG, KempMW, PayneMS, Spiller OB, Beeton
ML, et al. The paradoxical effects of chronic intra-amniotic Ureaplasma
parvum exposure on ovine fetal brain development. Dev Neurosci. (2017)
39:472–86. doi: 10.1159/000479021
35. Kemp MW, Ahmed S, Beeton ML, Payne MS, Saito M, Miura Y, et al.
Foetal Ureaplasma parvum bacteraemia as a function of gestation-dependent
complement insufficiency: evidence from a sheep model of pregnancy. Am J
Reprod Immunol. (2017) 77:e12599. doi: 10.1111/aji.12599
36. Wolfs TG, Kallapur SG, Knox CL, Thuijls G, Nitsos I, Polglase GR,
et al. Antenatal ureaplasma infection impairs development of the fetal
ovine gut in an IL-1-dependent manner. Mucosal Immunol. (2013) 6:547–
56. doi: 10.1038/mi.2012.97
37. Volpe JJ. Brain injury in premature infants: a complex amalgam of
destructive and developmental disturbances. Lancet Neurol. (2009) 8:110–
24. doi: 10.1016/S1474-4422(08)70294-1
38. Johnson CT, Adami RR, Farzin A. Antibiotic therapy for chorioamnionitis
to reduce the global burden of associated disease. Front Pharmacol. (2017)
8:97. doi: 10.3389/fphar.2017.00097
39. Ng PY, Ireland DJ, Keelan JA. Drugs to block cytokine signaling for the
prevention and treatment of inflammation induced preterm birth. Front
Immunol. (2015) 6:166. doi: 10.3389/fimmu.2015.00166
40. Keelan JA, Payne MS, Kemp MW, Ireland DJ, Newnham JP. A new,
potent, and placenta-permeable macrolide antibiotic, solithromycin, for
the prevention and treatment of bacterial infections in pregnancy. Front
Immunol. (2016) 7:111. doi: 10.3389/fimmu.2016.00111
41. Ophelders DR, Gussenhoven R, Lammens M, Küsters B, Kemp MW,
Newnham JP, et al. Neuroinflammation and structural injury of the fetal ovine
brain following intra-amniotic Candida albicans exposure. J Neuroinflamm.
(2016) 13:29. doi: 10.1186/s12974-016-0492-z
42. Paton MC, Allison BJ, Li J, Fahey MC, Sutherland AE, Nitsos I, et al.
Human umbilical cord blood therapy protects cerebral white matter from
systemic LPS exposure in preterm fetal sheep. Dev Neurosci. (2018) 40:258–
70. doi: 10.1159/000490943
43. Gomez-Lopez N, Romero R, Garcia-Flores V, Leng Y, Miller D, Hassan
SS, et al. Inhibition of the NLRP3 inflammasome can prevent sterile intra-
amniotic inflammation, preterm labor/birth, and adverse neonatal outcomes.
Biol Reprod. (2019) 100:1306–18. doi: 10.1093/biolre/ioy264
44. Galinsky R, Dhillon SK, Dean JM, Davidson JO, Lear CA, Wassink G,
et al. Tumor necrosis factor inhibition attenuates white matter gliosis after
systemic inflammation in preterm fetal sheep. J Neuroinflamm. (2020) 17:1–
16. doi: 10.1186/s12974-020-01769-6
45. Lacey L, Daulton E, Wicaksono A, Covington JA, Quenby S. Detection of
group B Streptococcus in pregnancy by vaginal volatile organic compound
analysis: a prospective exploratory study. Transl Res. (2020) 216:23–
9. doi: 10.1016/j.trsl.2019.09.002
46. Lacey L, Daulton E, Wicaksono A, Covington JA, Quenby S. Volatile
organic compound analysis, a new tool in the quest for preterm
birth prediction-an observational cohort study. Sci Rep. (2020) 10:1–
9. doi: 10.1038/s41598-020-69142-4
47. Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol.
(2015) 4:180–3. doi: 10.1016/j.redox.2015.01.002
48. Perrone S, Tataranno ML, Buonocore G. Oxidative stress and
bronchopulmonary dysplasia. J Clin Neonatol. (2012) 1:109–
14. doi: 10.4103/2249-4847.101683
49. Temma K, Shimoya K, Zhang Q, Kimura T,Wasada K, Kanzaki T, et al. Effects
of 4-hydroxy-2-nonenal, a marker of oxidative stress, on the cyclooxygenase-2
of human placenta in chorioamnionitis. Mol Hum Reprod. (2004) 10:167–
71. doi: 10.1093/molehr/gah030
50. Perrone S, Tataranno ML, Negro S, Longini M, Toti MS, Alagna MG, et al.
Placental histological examination and the relationship with oxidative stress in
preterm infants. Placenta. (2016) 46:72–8. doi: 10.1016/j.placenta.2016.08.084
51. Cheah FC, Jobe AH, Moss TJ, Newnham JP, Kallapur SG. Oxidative stress in
fetal lambs exposed to intra-amniotic endotoxin in a chorioamnionitis model.
Pediatr Res. (2008) 63:274–9. doi: 10.1203/PDR.0b013e31815f653b
52. Song Y, Pinniger GJ, Bakker AJ, Moss TJ, Noble PB, Berry CA, et al.
Lipopolysaccharide-induced weakness in the preterm diaphragm is associated
with mitochondrial electron transport chain dysfunction and oxidative stress.
PLoS ONE. (2013) 8:e73457. doi: 10.1371/journal.pone.0073457
53. Gould O, Ratcliffe N, Krol E, De Lacy Costello B. Breath analysis for detection
of viral infection, the current position of the field. J Breath Res. (2020)
14:041001. doi: 10.1088/1752-7163/ab9c32
54. Bos LD, Sterk PJ, Schultz MJ. Volatile metabolites of pathogens: a systematic
review. PLoS Pathog. (2013) 9:e1003311. doi: 10.1371/journal.ppat.10
03311
55. Boots AW, Smolinska A, Van Berkel JJ, Fijten RR, Stobberingh EE, Boumans
ML, et al. Identification of microorganisms based on headspace analysis of
volatile organic compounds by gas chromatography-mass spectrometry. J
Breath Res. (2014) 8:027106. doi: 10.1088/1752-7155/8/2/027106
56. Karami N, Karimi A, Aliahmadi A, Mirzajan F, Rezadoost H, Ghassempour
A, et al. Identification of bacteria using volatile organic compounds. Cell Mol
Biol (Noisy-le-grand). (2017) 63:112–21. doi: 10.14715/cmb/2017.63.2.18
57. Souza RT, Mckenzie EJ, Jones B, De Seymour JV, Thomas MM, Zarate E,
et al. Trace biomarkers associated with spontaneous preterm birth from
the maternal serum metabolome of asymptomatic nulliparous women—
parallel case-control studies from the SCOPE cohort. Sci Rep. (2019)
9:13701. doi: 10.1038/s41598-019-50252-7
58. Kim CJ, Romero R, Chaemsaithong P, Chaiyasit N, Yoon BH, Kim
YM. Acute chorioamnionitis and funisitis: definition, pathologic
features, clinical significance. Am J Obstet Gynecol. (2015)
213:S29–52. doi: 10.1016/j.ajog.2015.08.040
59. Payne MS, Ireland DJ, Watts R, Nathan EA, Furfaro LL, Kemp MW, et al.
Ureaplasma parvum genotype, combined vaginal colonisation with Candida
albicans, and spontaneous preterm birth in an Australian cohort of pregnant
women. BMC Preg Childbirth. (2016) 16:312. doi: 10.1186/s12884-016-
1110-x
60. Sweeney EL, Dando SJ, Kallapur SG, Knox CL. The human Ureaplasma
species as causative agents of chorioamnionitis. Clin Microbiol Rev. (2017)
30:349–79. doi: 10.1128/CMR.00091-16
61. Venkatesh K, Glover A, Vladutiu C, Stamilio D. Association of
chorioamnionitis and its duration with adverse maternal outcomes by
mode of delivery: a cohort study. BJOG Int J Obstet Gynaecol. (2019)
126:719–27. doi: 10.1111/1471-0528.15565
62. Fowler JR, Simon LV. Chorioamnionitis. StatPearls [Internet]. Treasure
Island, FL: StatPearls Publishing (2019). Available online at: https://www.ncbi.
nlm.nih.gov/books/NBK532251/
63. Blencowe H, Cousens S, Chou D, Oestergaard M, Say L, Moller AB, et al. Born
too soon: the global epidemiology of 15 million preterm births. Reprod Health
10 Suppl. (2013) 1:S2. doi: 10.1186/1742-4755-10-S1-S2
64. Oh KJ, Lee J, Romero R, Park HS, Hong J-S, Yoon BH, et al. A new rapid
bedside test to diagnose and monitor intraamniotic inflammation in preterm
PROM using transcervically collected fluid. Am J Obstet Gynecol. (2020)
223:423.e421–423. e415. doi: 10.1016/j.ajog.2020.02.037
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2021 Ophelders, Boots, Hütten, Al-Nasiry, Jellema, Spiller, van
Schooten, Smolinska and Wolfs. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and
the copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Pediatrics | www.frontiersin.org 9 May 2021 | Volume 9 | Article 617906
